Activity Description:

In this Build Your Own Case Study LIVE, “Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community,” learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study LIVE will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy.

Earn up to 1.0 CME/CE contact hours.

Space is limited, so REGISTER TODAY!

Agenda

  • Part 1: Exploring Innovative NHL Treatment Alternatives: Expert Insights on Integrating Clinical Guidelines into Decision-Making

  • Part 2: Constructing Patient Case Studies: Expert Conversations on Selecting Treatment Options and Patient Scenarios

  • Part 3: Cultivating Personalized Treatment Strategies through a Multidisciplinary Approach: Expert Discourse on Coordinated Care, Outpatient CAR T, and Patient-Centric Factors

  • Key Takeaways and Conclusions

  • Q&A with Expert Faculty

This activity is intended for hematologists/oncologists (community and academic), PAs, NPs, and other members of the interprofessional, multidisciplinary cancer care team on a global level that interface with patients with NHL.

After completing this CE activity, the participant should be better able to:

    • Assess the expanding treatment landscape for patients with NHL, including new and emerging non-CART options such as bispecific antibodies, and its impact on individualized treatment selection and treatment sequencing.
    • Analyze available CAR T-cell therapies for patients with relapsed/refractory NHL based on the latest safety and efficacy trial data and currently approved indications.
    • Conduct comprehensive evaluation to determine eligibility and potential benefits of CAR T-cell therapy based on recent clinical trial data, guideline recommendations, as well as patient-, disease-, and treatment-specific factors.
    • Identify suitable candidates that might benefit from CAR T-cell therapy in an outpatient setting versus an inpatient setting to support patient preference and satisfaction.
    • Apply a multidisciplinary approach to coordinate care between referring physician, establishing outpatient CART centers, and cross-collaboration with clinical teams to ensure individualized and optimal patient management. 

Joint Accreditation with Commendation LogoIn support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

This activity is provided by MLI

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

ECMEC(R) Credit

The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCMEâ) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMECâ) should contact the UEMS (www.uems.eu).

Physician Associate  

Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.65 contact hour in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

All disclosures will be provided to learners prior to the live presentation on Friday, May 31, 2024.

Support Statement
This activity is supported by an educational grant from Bristol Myers Squibb.

Symposium Location & Time

2024 ASCO Annual Meeting
Friday, May 31, 2024
6:00 PM – 6:30 PM Dinner 
6:30 PM – 7:30 PM Program

Hilton Chicago | Williford Room – 3rd Floor
720 South Michigan Avenue
Chicago, IL

Faculty

Christopher Flowers, MD, MS
Division Head ad Interim, Division of Cancer Medicine
Department Chair, Department of Lymphoma-Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
 
 

Catherine Coombs, MD
Associate Clinical Professor
Division of Hematology-Oncology
Department of Medicine
University of California, Irvine School of Medicine
Orange, CA, USA

 

Paolo F. Caimi, MD

Associate Professor
Cleveland Clinic Lerner College of Medicine
Staff Physician, Department of Hematology and Oncology
Cleveland Taussig Cancer Institute
Cleveland, OH, USA

Not an official event of the 2024 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

There are no fees for participating in or receiving credit for this CE activity, however, you must be registered for 2024 ASCO Annual Meeting.

Please enable JavaScript in your browser to complete this form.
Which of the following best represents your profession?
What is your primary work setting?
On average, how many individuals with NHL do you see every month?
1. Mr. H is a 62-year-old male with R/R MCL after receiving multiple lines of therapy, including chemotherapy + rituximab and ibrutinib followed by pirtobrutinib. Despite these treatments, his disease has further progressed. Mr. H has no significant comorbidities and is in good physical health aside from his MCL. What therapeutic strategy would you discuss with him as a next step?
2. Ms. S is a 64-year-old female with R/R CLL who received a BTK inhibitor and a BCL-2 inhibitor but has again relapsed. She has hypertension and type 2 diabetes, which are well-controlled. Based on currently approved indications, which therapy would be most appropriate?
3. For patients with CLL treated with lisocabtagene maraleucel on the TRANSCEND-004 trial, what were the incidences for grade 3 or higher cytokine release syndrome (CRS) and neurologic events (NE), respectively?
4. Mr. R is 59-year-old male with MCL, P53 wild type, stage IV disease with extranodal (gastrointestinal) involvement at diagnosis. He was initially treated with anthracycline- and cytarabine-containing chemoimmunotherapy followed by an autologous hematopoietic stem cell transplant. Three years later, he presents with new FDG avid retroperitoneal abdominal lymphadenopathy, without systemic symptoms. Biopsy is compatible with relapsed MCL. You discuss treatment options. Which of the following statements is correct relative to the appropriate treatment for this patient?
5. How confident are you regarding the selection of emerging CAR T-cell or non-CAR T-cell therapeutic options for the treatment of NHL?
Scroll to Top